Catalent Pharma Solutions Announces Commencement of Supply of Abilify® Orally Disintegrating Tablets to Otsuka Pharmaceutical Co., Ltd. and Extensive Investments to Its Zydis® Technology Capabilities in Swindon, UK

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent announced it has commenced supply to Otsuka Pharmaceutical Co., Ltd. of Abilify® OD Tablets (orally disintegrating tablets (ODT)), which utilize Catalent’s Zydis® fast dissolve drug delivery technology.